Does OCGN pay a dividend and is it safe?

Ocugen Inc. (OCGN) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / OCGN / dividends

FATE (35) LCTX (20) CABA (33) LXEO (33) ⌘ Pro Terminal →

Ocugen Inc. (OCGN) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.72 +3.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.72

Ocugen Inc. (OCGN) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $238.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OCGN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OCGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Ocugen Inc. (NASDAQ: OCGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $0.72 (+3.13% 1D, market cap $238.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OCGN ranks #924 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OCGN compare to FATE and LCTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OCGN carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FATE (Fate Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $249.2M) and LCTX (Lineage Cell Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M). Among the 5-stock peer group, OCGN leads on earnings multiple (N/A) while OCGN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OCGN?

▼

Per OCGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001372299), Ocugen Inc. generated $4.4M in revenue (+8.8% YoY), -$68.0M in net income, and -$57.1M in free cash flow against $43.5M in total assets and $27.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.72 (+0.37%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OCGN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (25/100 Composite)

🔍 WHY OCGN SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.88-8% Next Q

Q2 (-2Q)

Grade E$0.81-6.2% Next Q

Q3 (-1Q)

Grade E$0.76-5.3% Next Q

Current

Grade E$0.72-10.7% Hist 90D α

Trajectory: E (33) → E (25)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OCGN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OCGN currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.01) and Max Pain ($0.76) forces dealer call-delta covering toward $2.86.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OCGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OCGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 25%NO 75%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OCGN)

✓Walkthrough of OCGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OCGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.08%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.74H $0.74L $0.70C $0.72VOL 5.42M

RES: $1.19SUP: $0.68SMA50: $1.01SMA200: $1.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OCGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OCGN Butterfly Map → + Track OCGN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OCGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OCGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OCGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OCGN)

Health Care Rank #924 of 1015 ⚔️ FATE vs OCGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OCGN vs. FATE, LCTX, CABA, LXEO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Ocugen Inc. (OCGN) ranks #924 by composite RQD confidence (25/100, grade E) and #551 by equity capitalization ($238.3M). Within this direct 5-issuer industry benchmark cohort, OCGN leads on earnings valuation at N/A trailing P/E, while OCGN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with OCGN at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OCGN ACTIVE Ocugen Inc.	E	25/100	—	—	-35.0%	+3.13%	$238.3M	Benchmark Subject
FATE Fate Therapeutics Inc.	D-	35/100	—	—	-35.0%	-3.36%	$249.2M	/fate-vs-ocgn →
LCTX Lineage Cell Therapeutics Inc.	E	20/100	—	—	-35.0%	+1.00%	$252.9M	/lctx-vs-ocgn →
CABA Cabaletta Bio Inc.	E	33/100	—	—	-35.0%	-5.30%	$256.0M	/caba-vs-ocgn →
LXEO Lexeo Therapeutics Inc.	E	33/100	—	—	-35.0%	-2.55%	$257.6M	/lxeo-vs-ocgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001372299 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ocugen Inc. (OCGN) reported GAAP revenue of $4.4M (+8.8% vs. FY2024 revenue of $4.1M , and -26.9% cumulative change since FY2023) , GAAP net income of -$68.0M, operating cash flow of -$57.0M, and free cash flow of -$57.1M (-25.5% YoY). On the balance sheet, OCGN closed FY2025 with $43.5M in total assets against $27.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.4M	-$68.0M	-$57.0M	-$57.1M	$43.5M	$27.5M
FY2024 (FY)	2024-12-31	$4.1M	-$54.0M	-$42.1M	-$45.5M	$82.4M	$27.3M
FY2023 (FY)	2023-12-31	$6.0M	-$63.0M	-$62.1M	-$62.1M	—	—

3. OCGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OCGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OCGN compare to FATE and LCTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OCGN?

Where is OCGN trading relative to its 50-day, 200-day, and 52-week technical levels?

OCGN last traded at $0.72 (+3.13% on volume of 5,712,779 shares), positioning the stock -28.71% below its 50-day simple moving average ($1.01) and -49.30% below its 200-day simple moving average ($1.42). Across its 52-week range of $0.69 to $2.72, OCGN sits at the 1.5% percentile with a 14-day RSI of 31.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).

Direct Sub-Reports: OCGN RQD Cockpit OCGN 12M Forecast OCGN Earnings & Move OCGN Dividends & DRIP OCGN Insiders & 13F OCGN Whale Options OCGN Profit Sankey OCGN News & Why

ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ SEC XBRL & RQD VERIFIED

OCGN — Ocugen Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Ocugen Inc. (OCGN) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.72 (+3.13% 1D, market capitalization $238.3M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -22.65%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Ocugen Inc. (OCGN) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $0.3B. Per the news wire, the company's programs include three gene therapy programs for blindness, with key data expected in 2027 and 2028.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Ocugen Inc. (OCGN) reported $4.4M in annual revenue (up from $4.1M in FY2024, +8.8% YoY) and -$68.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.0M revenue, -$63.0M net income) through FY2025, OCGN scaled operating cash flow to -$57.0M and free cash flow to -$57.1M, backed by $43.5M in total assets against $27.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 25/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -22.65% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.69 – $2.72 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), OCGN carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can OCGN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $4.4M and free cash flow of -$57.1M, how will capital allocation balance growth reinvestment against $27.5M in total debt?
Key Question #3: How sensitive is OCGN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OCGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ocugen Inc. (OCGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OCGN Debate Forum (3) ↓

🟡 MARKET WIRE Investing.com • 22h ago

Ocugen CEO Shankar Musunuri sells $499,691 of company stock

Investing.com report covering Ocugen Inc. (OCGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Ocugen(OCGN) Stock Options Chain | Quotes & News

Moomoo report covering Ocugen Inc. (OCGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An officer proposes selling 525,991 Ocugen (OCGN) shares through Merrill Lynch.

Stock Titan report covering Ocugen Inc. (OCGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Ocugen (NasdaqCM:OCGN) Stock Forecast & Analyst Predictions

Simply Wall St report covering Ocugen Inc. (OCGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Transcript: Ocugen Q2 2026 Earnings Conference Call

Benzinga report covering Ocugen Inc. (OCGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Key data from Ocugen's three gene therapy programs for blindness are expected in 2027 and 2028.

Stock Titan report covering Ocugen Inc. (OCGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE PR Newswire • 1d ago

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PR Newswire report covering Ocugen Inc. (OCGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Ocugen stock schedules two November gene therapy appearances

ad-hoc-news.de report covering Ocugen Inc. (OCGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OCGN Bull vs. Bear Conversation Board — What's Your Call at $0.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OCGN 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $0.82 (+17.1%)

📌 Pinned Debate

The balance-sheet pillar (8/20) is the strongest of the five, with cash of $18.6M against debt of $27.5M and a 2.5 Altman Z-Score, indi

The street is overcomplicating Ocugen Inc. (OCGN). The balance-sheet pillar (8/20) is the strongest of the five, with cash of $18.6M against debt of $27.5M and a 2.5 Altman Z-Score, indicating the company is not in immediate distress by these measures.. With an RQD score of 25/100 (E) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.76.

VolSurface_Trader 🐂 BULL

Both sides have a point here — OCGN's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.57 (-18.6%)

Spot @ $0.70

FY 2025 free cash flow of -$57.1M against $18.6M of cash and a -22.65% FCF yield signals that the company's cash burn far exceeds its a

I respect the product at Ocugen Inc., but the stock at $0.70 is a different story. FY 2025 free cash flow of -$57.1M against $18.6M of cash and a -22.65% FCF yield signals that the company's cash burn far exceeds its available liquidity.. FCF yield is -22.65% and RQD sits at 25/100 (E) — why pay up here when you can wait for next quarter's numbers?